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Abstract
Background: This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in
Southern Taiwan for the period 2001–2012 and analyze the risk factors for acquiring it among patients with invasive
cryptococcosis.
Methods: All enrolled strains were isolated from blood or cerebrospinal fluid samples of the included patients. If a
patient had multiple positive results for C. neoformans, only the first instance was enrolled. Susceptibility testing was
performed using the Clinical and Laboratory Standards Institutes M27-A3 broth micro-dilution method. The MIC
interpretative criteria for susceptibility to fluconazole were ≤8 μg/ml. A total of 89 patients were included. Patients
(n = 59) infected by fluconazole-susceptible strains were compared with those (n = 30) infected by non-susceptible
strains. The patients’ demographic and clinical characteristics were analyzed.
Results: The rate of fluconazole-non-susceptible C. neoformans in the study period significantly increased over time
(p < 0.001). The C. neoformans isolated in 2011–2012 (odds ratio: 10.68; 95 % confidence interval: 2.87-39.74;
p < 0.001) was an independent predictive factor for the acquisition of fluconazole-non-susceptible C. neoformans.
Conclusions: The rate of fluconazole-non-susceptible C. neoformans has significantly increased recently. Continuous
and large-scale anti-fungal susceptibility tests for C. neoformans are warranted to confirm this trend.
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Background
Cryptococcus neoformans is an encapsulated yeast re-
sponsible for life-threatening infections [1]. Pharmaco-
logic management usually consists of primary therapy
with amphotericin B, with or without flucytosine,
followed by maintenance therapy with fluconazole [2].
Pre-emptive fluconazole therapy for positive serum
cryptococcal antigen in patients with human immuno-
deficiency virus (HIV) to prevent the development of
cryptococcal meningitis is also regarded as cost effective
for specific groups [3]. The widespread use of flucona-
zole for long-term suppressive therapy of cryptococcal
infection has become a concern due to the development
of fluconazole resistance [4, 5]. Yet despite these con-
cerns, in vitro susceptibility testing of C. neoformans iso-
lates at the start of therapy is not routinely practiced [2].
Instead, it is reserved for patients with failed primary
therapy, those with relapse, or those who develop
cryptococcosis and have recent exposure to an anti-
fungal drug [2].
In the guidelines of the Infectious Diseases Society of
America (IDSA), primary resistance of C. neoformans to
fluconazole is not a significant clinical problem, as noted
in a previous study [6]. In a national surveillance in
Taiwan in 2003, only three of 70 (4 %) C. neoformans
clinical isolates had MICs of fluconazole at concentra-
tions ≥16 μg/ml [7]. Another population-based surveil-
lance in South Africa on C. neoformans isolates
collected before 2008 still maintained low MIC values
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to fluconazole [8]. However, the development of mi-
crobial resistance is dynamic. The issue of using azoles
and C. neoformans resistance has been described [9].
A previous study has found that the MIC90 of flucona-
zole against C. neoformans increased from 4 to 16 μg/ml
in cerebrospinal fluid (CSF) specimens collected between
2001 and 2010 [10]. High rates of C. neoformans persist-
ence and frequent relapses have sparked concern for the
possible emergence of fluconazole resistance [11]. In-
creasing in vitro resistance to fluconazole in C. neofor-
mans isolates has also been proposed [12]. A previous
study has elucidated a correlation between fluconazole
susceptibility and clinical outcome in patients with
cryptococcal meningitis [10]. Thus, an updated surveil-
lance of anti-fungal susceptibility of the clinical strain of
C. neoformans is desirable to monitor the trend of flu-
conazole non-susceptible strains [13].
The current study aimed to evaluate the in vitro sus-
ceptibility of clinical C. neoformans isolates against flu-
conazole between 2001 and 2012 in Southern Taiwan. It
also analyzed the risk factors for acquiring fluconazole-
non-susceptible C. neoformans among patients with
invasive cryptococcosis, which was defined as C. neofor-
mans escape from the lungs and entering the blood-




C. neoformans isolated from patients with invasive
cryptococcosis were collected. If the patient had more
than one episode of invasive cryptococcosis, only the
first episode was included. All enrolled clinical strains
were isolated from blood or CSF samples of patients
who were admitted to Kaohsiung Chang Gung Memorial
Hospital (KCGMH) between January 2001 and Decem-
ber 2012. The KCGMH was a 2700-bed primary care
and tertiary referral center in Southern Taiwan. If a pa-
tient had multiple positive results for C. neoformans,
only the first isolate was enrolled for in vitro analysis.
This study followed previously published studies and
included 46 clinical strains from CSF samples as de-
scribed previously [10]. To determine the risk factors for
acquiring fluconazole-non-susceptible C. neoformans,
demographic and clinical information were retrieved
from medical records retrospectively. The Chang Gung
Memorial Hospital’s Institutional Review Board ap-
proved the study [No. 102-3819B].
Data collection and definition
Data on clinical variables included age, sex, and under-
lying diseases (i.e., AIDS, diabetes mellitus, receiving
hemodialysis, chronic kidney disease, liver cirrhosis,
chronic lung disease, steroids usage, malignancy,
hematologic malignancy, and autoimmune disease).
The use of azoles was defined as the intake of flucona-
zole, itraconazole, voriconazole, or ketoconazole for
more than 48 h within three months prior to the first
episode of invasive cryptococcosis. Steroid use was de-
fined as the intake of at least 10 mg prednisolone or its
equivalent per day for more than two months prior to
the infection. The severity of illness at the time of CSF
or blood sampling was assessed using the APACHE II
scoring method [15] modified as 0 point given to the
items PaO2 and pH if arterial blood gas analysis was
not performed because of the absence of respiratory
distress.
Sepsis was defined as a systemic response to infection,
manifested by two or more of the following conditions:
(1) temperature >38 °C or <36 °C; (2) heart rate >90
beats per minute; (3) respiratory rate >20 breaths per
minute or PaCO2 < 32 mm Hg; and white blood cell
count >12,000 cells/mm3, <4,000 cells/mm3, or >10 %
immature (band) forms [16]. Septic shock was diagnosed
if there was refractory hypotension, signifying that intra-
venous fluid administration alone was insufficient to
maintain adequate blood pressure [16]. The collected la-
boratory data was on leukocytes, hemoglobin, platelet
count, percentage of neutrophils and lymphocytes, and
presentation of high titers of CSF and serum crypto-
coccal antigen defined as more than 1:512 if these data
were available.
Fungal strain
The processing of specimens and identification of iso-
lates were performed by conventional methods using the
Vitek Yeast Biochemical Card (BioMerieux, Marcy
l’Etoile, France) [17]. The isolated strains were preserved
at −70 °C until the experiments.
Isolation of genomic DNA and PCR amplification
Each strain was grown on SDA plates at 35 °C for two
days. Cells were collected and suspended in a TE buffer
(100 mM Tris–HCl; pH 8.0, 1 mM EDTA) containing
lyticase (Sigma, St. Louis, MO, USA). Glass beads
(Sigma) were then added to the micro-tubes and the
samples were incubated at 37 °C for 4 h, and mixed in
an end-over-end mixer to digest the cell walls. Genomic
DNA was extracted from the cells using the High Pure
PCR template preparation kit (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s
instructions.
The serotype of C. neoformans was identified by multi-
plex PCR. Four primers for cloning laccase gene (LAC1)
and two for capsule gene (CAP64) were used [18]. The
LAC1 differentiated serotypes A, D, B and C and CAP64
differentiated serotypes D and AD. CNa-70-S and CNa-
70-A primer pair (amplified a 695-bp DNA fragment
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from serotype A), CNa-29-S and CNa-29-A primer pair
(amplified a 579-bp fragment from serotype A), CNa-29-
S and CNa-70-A primer pair (amplified a 666-bp or a
460-bp fragment from serotype A, 290-bp from serotype
B or C) and CNb-49-S and CNb-49-A primer pair (amp-
lified a 448-bp fragment from serotype B or serotype C)
were used [19]. The amplified products were separated
by electrophoresis and stained with ethidium bromide.
The DNA bands were extracted using a gel extraction
kit (QIAquick, QIAGEN Sciences, Germantown, MD,
USA) and sequenced directly using a BigDye Terminator
Cycle-sequencing kit (ABI PRISM 310NT Genomic
Analyzer, Perkin-Elmer Applied Biosystems, Foster, CA,
USA).
Fluconazole susceptibility testing
Fluconazole (Pfizer, New York, NY, USA) susceptibilities
were determined using the broth micro-dilution method
according to the CLSI M27-A3 methodology [20]. Stock
solutions were prepared in water and further diluted in
RPMI 1640 medium (Sigma) buffered to a pH of 7 with
0.165 M 3-(N-morpholino) propanesulfonic acid buffer
(Sigma). Aliquots of each agent (0.1 ml) at two-times the
concentrations were dispensed into 96-well micro-dilution
trays. The yeast inoculum was adjusted to a concentration
of 104 CFU/mL before being added to each well. The trays
were incubated at 35 °C. The final fluconazole concentra-
tions ranged from 0.25 to 64 μg/ml.
The MICs for fluconazole were the concentrations
causing a 50 % reduction in turbidity compared to the
growth of the control at 72 h. Candida krusei ATCC
6258 and Candida parapsilosis ATCC 22019 were used
as quality controls. The interpretative criterion for sus-
ceptibility to fluconazole was ≤8 μg/ml, as published by
the CLSI [20]. The reproducibility of the in vitro results
was assessed twice on two different days. The geometric
mean fluconazole MIC was evaluated each year during
the study period.
Statistical analysis
The annual fluconazole-non-susceptible rate of C. neo-
formans isolated from the patients was calculated. Chi-
square test for a linear regression analysis was performed
to determine the trends of fluconazole-non-susceptible
rates of C. neoformans isolated from 2001 to 2012, while
simple linear regression was used to estimate the trends
of geometric mean fluconazole MIC during the study
period. By univariate analysis, continuous variables were
expressed as mean ± standard deviation and values were
compared by Student’s t test. Categorical variables,
expressed as numbers and percentages, were compared
by chi-square test or Fisher’s exact test, as appropriate.
To identify risk factors for acquiring fluconazole-non-
susceptible C. neoformans, the patients were categorized
as those with fluconazole-non-susceptible (Group 1) or
with fluconazole-susceptible (Group 2) C. neoformans.
Statistically significant variables in univariate analyses
between these categories were entered into multivariate
analysis using a logistic regression model. Statistical sig-
nificance was set at a two-tailed p < 0.05. Statistical ana-
lysis was conducted using the SPSS statistical analysis
system (ver.21).
Results
During the study period, 93 isolates of Cryptococcus spe-
cies were identified from blood (n = 48) and CSF (n = 45)
samples. Eighty-nine isolates were C. neoformans var. gru-
bii (serotype A) and 4 were C. gattii (serotype B). Of the
89 C. neoformans isolates, 30 (34 %) were fluconazole-
non-susceptible (MICs ≥16 μg/ml). The 89 patients with
invasive cryptococcosis were categorized as those who
infected by fluconazole non-susceptible C. neoformans
(Group 1, n = 30) and those infected by fluconazole sus-
ceptible C. neoformans (Group 2, n = 59). The annual
rate of fluconazole non-susceptible C. neoformans iso-
lated from 2001 to 2012 significantly increased over
time (p < 0.001). The annual rate of fluconazole non-
susceptible C. neoformans was 0-33 % in 2001–2006,
18-29 % in 2007–2010, and 75-86 % in 2011–2012
(Fig. 1). There is also a significantly increasing trend
over time in the geometric mean fluconazole MIC
(p < 0.01). Clinical strains cultured in 2011–2012
were specified to clarify the emergence of fluconazole-
non-susceptible strains.
The demographic and clinical features and serotypes
of C. neoformans strains between the two groups were
compared (Table 1). Except for the lower proportion of
liver cirrhosis in Group 1 (3 % vs. 24 %, p = 0.02), the
demographic and clinical features were similar in the
two groups. Patients in Group 1 had a predominated ad-
mission during 2011–2012 (50 % vs. 7 %, p < 0.001), pre-
vious azole exposure (24 % vs. 7 %, p = 0.04), and initial
presentation as sepsis (70 % vs. 46 %, p = 0.03).
In multivariate analysis, patient admission in 2011–
2012 (odds ratio, OR: 10.68; 95 % confidence interval,
CI: 2.87-39.74; p < 0.001) was an independent predictive
factor for acquiring fluconazole-non-susceptible C. neo-
formans (Table 2).
Discussion
The current study demonstrated that the rate of flucona-
zole non-susceptible C. neoformans from 2001 to 2012
significantly increased over time (p < 0.001). A high
fluconazole-non-susceptible rate was especially recog-
nized in the last two years (2011–2012). In the past, the
development of secondary resistance to fluconazole dur-
ing therapy was given more attention than primary re-
sistance. During the 12-year study period, there were 89
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C. neoformans initial clinical isolates from patients with
invasive cryptococcosis, including 30 (34 %) non-
susceptible to fluconazole.
The rate of fluconazole non-susceptible C. neoformans
in the present study is higher than those of previous
studies [6, 7, 21]. Thus, non-susceptibility to fluconazole
has become a growing problem. A global anti-fungal sur-
veillance study conducted from 1997 to 2007 documents
a progressive increase in resistance to fluconazole among
C. neoformans isolates when results from the time pe-
riods 1997 to 2000 (7.3 %), 2001 to 2004 (10.9 %), and
2005 to 2007 (11.7 %) are compared [22]. The problem
is especially true among isolates from the Asia-Pacific,
Africa/Middle East, and Latin America compared to iso-
lates from Europe or North America [22].
In Asia, most invasive cryptococcosis cases are caused
by C. neoformans var. grubii [23, 24]. Similarly, 95.7 %
(89/93) of C. neoformans isolates from the present study
belong to serotype A. One previous study has demon-
strated that strains of serotype A are less susceptible to
fluconazole than strains of serotype D [21]. Using micro-
satellite analysis, there is a different distribution of geno-
types of C. neoformans var. grubii isolates in various
countries in Asia, as well as a correlation of the micro-
satellite genotypes with the original source of the strain
and resistance to anti-fungal agents [25]. Recently, a
nationwide multi-center retrospective study in Taiwan
has suggested that C. neoformans isolates with anti-
fungal MIC higher than the epidemiologic cut-off values
are rare (one of 203 isolates had fluconazole MIC levels
>8 μg/mL) [26, 27]. In Spain, 58 C. neoformans clinical
isolates were collected from 1990 to 2007. Only 2 strains
isolated from HIV patients were fluconazole MIC of
16 μg/ml (3.4 %) [28]. Although the number of flucona-
zole non-susceptible C. neoformans is small according to
these two recent studies, the clinical isolates have been
obtained before 2010 [27, 28].
In the present study, more patients infected by
fluconazole-non-susceptible C. neoformans strains ex-
perienced azole exposure recently than those infected
by fluconazole-susceptible C. neoformans strains. The
azole exposure in our study is not an independent risk
factor for invasive cryptococcosis caused by fluconazole-
non-susceptible C. neoformans under the multivariate
analysis, but the exposure history of our patients may be
underestimated because of retrospective study nature.
One case series showed that 70 % of patients with
fluconazole-resistant cryptococcosis had history of prior
exposure to fluconazole [29]. Therefore, the IDSA guide-
lines for the management of cryptococcal disease recom-
mended in-vitro susceptibility testing should be reserved
for patients had recent exposure to an antifungal drug [2].
Fig. 1 The annual rate (black line) of fluconazole non-susceptible (MICs ≥16 μg/ml) Cryptococcus neoformans from 2001 to 2012 significantly
increased over time (p < 0.001). There was also an increasing trend of geometric mean fluconazole MIC during the study period (p < 0.01)
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The ability of C. neoformans to develop azole resist-
ance is dependent on several mechanisms, including
drug target alterations encoded by the gene ERG11,
which may be obtained through mutations or by over-
expression of the gene encoding, over-expression of ef-
flux pumps, and modulation of stress signaling pathways
[30]. Moreover, a pattern of cellular responses to the
azoles in C. neoformans has been reported, as well as the
term hetero-resistance, which occurs when a single cell
gives rise to a progeny with heterogeneous resistance
phenotypes, even with a small subset of progeny that are
highly resistant to azole [31, 30]. The resistant sub-
population can adapt to increasing concentrations of
azoles in a stepwise manner [30]. The formation of di-
somic chromosomes in response to fluconazole stress is
closely associated to ERG11 and AFR1, the major trans-
porter of azoles in C. neoformans in both serotypes A
and D [32]. That is an adaptive mechanism in C. neofor-
mans that plays an important role in the failure of flu-
conazole therapy on cryptococcosis [32].
Pan et al. report that fluconazole has the broadest
(0.125-32 μg/mL) and the highest MIC value, and lowest
activity (MIC90 = 4 μg/mL) against C. neoformans com-
pared to other azoles like intraconazole, voriconazole,
Table 1 Risk factors for invasive cryptococcosis caused by fluconazole-non-susceptible C. neoformans
Variables Group 1, n = 30 (%) Group 2, n = 59 (%) p
Age 53.8 ± 17.9 58.3 ± 17.8 0.27
Male: female 21:9 37:22 0.50
Admissions 2011-2012 15 (50) 4 (7) <0.001
Azole exposurea 7 (24) 4 (7) 0.04
Co-morbidity
HIV infection 6/17b (35) 7/36c (19) 0.31
Diabetes mellitus 7 (23) 20 (34) 0.31
Hemodialysis 3 (10) 2 (3) 0.33
Chronic kidney disease 4 (13) 8 (14) 1.00
Liver cirrhosis 1 (3) 14 (24) 0.02
Chronic lung disease 1 (3) 7 (12) 0.26
Steroid user 11 (37) 21 (36) 0.92
Solid cancer 6 (20) 5 (8) 0.17
Hematologic malignancy 3 (10) 4 (7) 0.68
Autoimmune disease 2 (7) 5 (8) 1.00
Disease severity
APACHE-II score 12.1 ± 8.1 13.9 ± 9.2 0.37
Septic shock 1 (3) 12 (20) 0.05
Sepsis 21 (70) 27 (46) 0.03
Laboratory
Leukocyte count (1000/mm3) 10.46 ± 7.47 9.94 ± 6.66 0.74
Hemoglobin (mg/dL) 11.02 ± 2.16 11.44 ± 2.37 0.43
Platelet count (1000/mm3) 156.90 ± 107.89 162.44 ± 98.82 0.81
Neutrophil (%) 78.44 ± 13.40 82.37 ± 12.14 0.18
Lymphocyte (%) 12.84 ± 9.99 10.23 ± 8.33 0.20
Serum cryptococcal Ag >1: 512 11/19d (58) 12/31e (39) 0.19
CSF cryptococcal Ag >1:512 13/20f (65) 16/30g (53) 0.41
Specimen from CSF 15 (50) 30 (51) 1.00
Azole exposurea: Patients who received azole therapy (fluconazole, voriconazole, itraconazole, or ketoconazole) for more than 48 h within 3 months prior to the
first episode of invasive cryptococcosis
HIV human immuno-deficiency virus, CSF cerebrospinal fluid, Group 1, patients infected by fluconazole non-susceptible C. neoformans (minimal inhibitory
concentrations of fluconazole ≥ 16 μg/ml); Group 2, patients infected by fluconazole susceptible C. neoformans
b9; c37: Numbers of patients with HIV serology test
d11; e33: Numbers of patients with serum cryptococcus Ag
f11; g32: Numbers of patients with CSF cryptococcus Ag
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posaconazole, and isavuconazole. These new generation
triazoles may become an important therapeutic choice
to currently used anti-fungals [25].
This study still has several limitations. It is a single
center study. Differences in fluconazole-susceptibility
rates may exist owing to geographical variations. The
retrospective use of patient medical record usually
means that some data are missing or misclassified and
not all of the patients have been checked for HIV. The
number of patients or duration of azole exposure may
be underestimated. In addition, drug exposure has not
been quantified definitely. These factors may yield more
conservative results. This 12-years longitudinal study
continuously investigates the susceptibility of C. neofor-
mans against fluconazole. In the last two years, there has
been increasing fluconazole non-susceptibility. The pos-
sibility of a clonal phenomenon associated with flucona-
zole non-susceptibility is doubtful. However, all patients
with invasive cryptococcosis have been diagnosed spor-
adically for the study period (2001–2012). There is no
relationship to admission date and inhabited area among
these patients. Further studies with genotyping by pulsed
field gel electrophoresis and mating type are needed.
Nevertheless, the results here serve to remind clinicians
that primary resistance to fluconazole of C. neoformans
may not be persistently low.
Conclusions
This study reveals that the fluconazole non-susceptibility
of C. neoformans has increased in the last two years of
this 12-year longitudinal study. Continuous and large-
scale anti-fungal susceptibility tests for C. neoformans
are necessary to confirm this trend.
Abbreviations
CLSI: Clinical and laboratory standards institutes; MIC: Minimal inhibitory
concentration; HIV: Human immune-deficiency virus; IDSA: Infectious disease
society of America; CSF: Cerebrospinal fluid; CNS: Central venous system;
KCGMH: Kaohsiung Chang Gung Memorial Hospital; AIDS: Acquired
immunodeficiency syndrome; APACHE II: Acute physiology and chronic
health evaluation II; PaO2: Partial pressure of oxygen in arterial blood;
PaCO2: Partial pressure of carbon dioxide in arterial blood; PCR: Polymerase
chain reaction; DNA: Deoxyribonucleic acid; SDA: Sabouraud dextrose agar;
RPMI: Roswell Park Memorial Institute.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YCC, TYC, JWL, FJC, CCC, CHLee and CHLu participated in the design of this
study. FJC, CCC, and CHLee developed the in vitro assay. YCC, CHLee, and
CHLu wrote the manuscript. All of the authors read and approved the final
manuscript.
Acknowledgements
This study was supported by grants from Chang Gung Memorial Hospital,
Taiwan (CMRPG 8B0671). The authors thank Dr. Gene Alzona Nisperos for
editing and reviewing the manuscript for English language considerations.
Author details
1Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung
Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 2Chang Gung University
College of Medicine, 123 Ta-Pei RoadNiao-Sung District, Kaohsiung City 833,
Taiwan. 3Department of Laboratory Medicine, Kaohsiung Chang Gung
Memorial Hospital, Kaohsiung, Taiwan. 4Department of Neurology, Kaohsiung
Chang Gung Memorial Hospital, 123 Ta-Pei RoadNiao-Sung District,
Kaohsiung City 833, Taiwan. 5Department of Biological Science, National Sun
Yat-Sen University, Kaohsiung, Taiwan.
Received: 28 December 2014 Accepted: 13 July 2015
References
1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS–100 years after
the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–48.
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al.
Clinical practice guidelines for the management of cryptococcal disease:
2010 update by the Infectious Diseases Society of America. Clin Infect Dis.
2010;50:291–322.
3. Patel S, Shin GY, Wijewardana I, Vitharana SR, Cormack I, Pakianathan M,
et al. The prevalence of cryptococcal antigenemia in newly diagnosed HIV
patients in a Southwest London cohort. J Infection. 2013;66:75–9.
4. Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole
prophylaxis for patients with AIDS. Clin Infect Dis. 1998;26:186–7.
5. Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist
Updat. 1999;2:259–69.
6. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al. In vitro
susceptibilities of yeast species to fluconazole and voriconazole as
determined by the 2010 National China Hospital Invasive Fungal
Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012;50:3952–9.
7. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, et al. Anti-
fungal susceptibilities of clinical isolates of Candida species, Cryptococcus
neoformans, and Aspergillus species from Taiwan: surveillance of multi-center
antimicrobial resistance in Taiwan program data from 2003. Antimicrob
Agents Chemother. 2005;49:512–7.
8. Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR, Group for Enteric
R, et al. Trends in anti-fungal drug susceptibility of Cryptococcus neoformans
isolates obtained through population-based surveillance in South Africa in
2002–2003 and 2007–2008. Antimicrob Agents Chemother. 2011;55:2606–11.
9. Gullo FP, Rossi SA, Sardi Jde C, Teodoro VL, Mendes-Giannini MJ, Fusco-Almeida
AM. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for
treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1377–91.
10. Lee CH, Chang TY, Liu JW, Chen FJ, Chien CC, Tang YF, et al. Correlation of
anti-fungal susceptibility with clinical outcomes in patients with
cryptococcal meningitis. BMC Infect Dis. 2012;12:361.
11. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic
relapse of HIV-associated cryptococcal meningitis after initial fluconazole
monotherapy: the role of fluconazole resistance and immune reconstitution.
Clin Infect Dis. 2006;43:1069–73.
12. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro
resistance to fluconazole in Cryptococcus neoformans Cambodian isolates:
April 2000 to March 2002. J Antimicrob Chemother. 2004;54:563–5.
Table 2 Stepwise multiple logistic regression analysis of risk
factors associated with invasive cryptococcosis due to
fluconazole-non-susceptible C. neoformansb
Factors Comparison OR (95 % CI) p
Admission during 2011-2012 Yes vs. No 10.68 (2.87-39.74) <0.001
Liver cirrhosis Yes vs. No 0.17 (0.02-1.58) 0.12
Initial present with sepsis Yes vs. No 1.86 (0.62-5.62) 0.27
Azole exposurea Yes vs. No 3.33 (0.73-15.25) 0.12
Azole exposurea: patients received azole therapy (fluconazole, voriconazole,
itraconazole, or ketoconazole) for more than 48 h within 3 months prior to the
first episode of invasive cryptococcosis
OR odds ratio, CI confidence interval
bStatistically significant variables in univariate analyses between these
categories were entered into multivariate analysis using a logistic regression
model. Statistical significance was set at a two-tailed p < 0.05
Chen et al. BMC Infectious Diseases  (2015) 15:277 Page 6 of 7
13. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, et al.
In vitro anti-fungal susceptibility profiles and genotypes of 308 clinical and
environmental isolates of Cryptococcus neoformans var. grubii and
Cryptococcus gattii serotype B from north-western India. J Med Microbiol.
2011;60:961–7.
14. Eisenman HC, Casadevall A, McClelland EE. New insights on the
pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis
Rep. 2007;9:457–64.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med. 1985;13:818–29.
16. American College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference: definitions for sepsis and organ failure and
guidelines for the use of innovative therapies in sepsis. Crit Care Med.
1992;20:864–74
17. Fenn JP, Segal H, Barland B, Denton D, Whisenant J, Chun H, et al.
Comparison of updated Vitek Yeast Biochemical Card and API 20C yeast
identification systems. J Clin Microbiol. 1994;32:1184–7.
18. Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of
Cryptococcus neoformans by multiplex PCR. Mycoses. 2007;50:277–81.
19. Aoki FH, Imai T, Tanaka R, Mikami Y, Taguchi H, Nishimura NF, et al. New
PCR primer pairs specific for Cryptococcus neoformans serotype A or B
prepared on the basis of random amplified polymorphic DNA fingerprint
pattern analyses. J Clin Microbiol. 1999;37:315–20.
20. Clinical and Laboratory Standards Institute (CLSI). Reference method for
broth dilution anti-fungal susceptibility testing of yeasts; approved standard.
3rd ed. Wayne, PA: CLSI document M27–A3, CLSI; 2008.
21. Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, et al.
Results obtained with various anti-fungal susceptibility testing methods do
not predict early clinical outcome in patients with cryptococcosis.
Antimicrob Agents Chemother. 2006;50:2464–70.
22. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al.
Results from the ARTEMIS DISK Global Anti-fungal Surveillance Study, 1997
to 2007: 10.5-year analysis of susceptibilities of non-candidal yeast species
to fluconazole and voriconazole determined by CLSI standardized disk
diffusion testing. J Clin Microbiol. 2009;47:117–23.
23. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ.
Cryptococcus neoformans strains and infection in apparently immuno-
competent patients, China. Emerg Infect Dis. 2008;14:755–62.
24. Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, Carriconde F,
et al. Prevalence of the VNIc genotype of Cryptococcus neoformans in
non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res.
2010;10:769–78.
25. Pan W, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A,
et al. Resistance of Asian Cryptococcus neoformans serotype A is confined to
few microsatellite genotypes. PLoS One. 2012;7:e32868.
26. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A,
Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species
complex: an international study of wild-type susceptibility endpoint
distributions and epidemiological cutoff values for fluconazole, itraconazole,
posaconazole, and voriconazole. Antimicrob Agents Chemother.
2012;56:5898–906.
27. Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. Microbiological,
epidemiological, and clinical characteristics and outcomes of patients with
cryptococcosis in Taiwan, 1997–2010. PLoS One. 2013;8:e61921.
28. Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M,
et al. Antifungal susceptibility, serotyping, and genotyping of clinical
Cryptococcus neoformans isolates collected during 18 years in a single
institution in Madrid, Spain. Med Mycol. 2010;48:942–8.
29. Cheong JW, McCormack J. Fluconazole resistance in cryptococcal disease:
emerging or intrinsic? Med Mycol. 2013;51:261–9.
30. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal
development, drug resistance, and disease. Microbiol Mol Biol Rev.
2011;75:213–67.
31. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, et al.
Hetero-resistance to fluconazole and voriconazole in Cryptococcus
neoformans. Antimicrob Agents Chemother. 1999;43:1856–61.
32. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans
overcomes stress of azole drugs by formation of disomy in specific multiple
chromosomes. PLoS Pathog. 2010;6:e1000848.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chen et al. BMC Infectious Diseases  (2015) 15:277 Page 7 of 7
